{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:14:55Z","timestamp":1794896095902,"version":"4.9.1"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>Genitourinary syndrome of menopause (GSM) encompasses the symptoms of estrogen deprivation in the vaginal, vulva, and bladder areas. Because many cancer treatments induce a hypoestrogenic state, GSM is common in cancer survivors. The number of cancer survivors is increasing, and the unique aspects of GSM management for cancer survivors, such as the safety of hormonal therapies, is important to understand. In this review, we cover important considerations in the assessment of GSM; nonpharmacologic, behavioral, integrative, pharmacologic, and medical device treatments for GSM: the unique considerations in GSM by cancer treatment modality; bladder manifestations of GSM; and GSM in specific populations.<\/jats:p>","DOI":"10.1097\/grf.0000000000000848","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T08:00:11Z","timestamp":1702886411000},"page":"89-100","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Genitourinary Syndrome of Menopause in Cancer Survivors"],"prefix":"10.1097","volume":"67","author":[{"given":"CATHERINE L.","family":"DUGAN","sequence":"first","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALISHA A.","family":"OTHIENO","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MINDY E.","family":"GOLDMAN","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco"},{"name":"Midi Health, Menlo Park, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"R1-20250512","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1007\/s13187-019-01559-6","article-title":"Discussing sexual health in the Medical Oncologist\u2019s Practice: exploring current practice and challenges","volume":"35","author":"Krouwel","year":"2020","journal-title":"J Cancer Educ"},{"key":"R3-20250512","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/13697137.2013.819327","article-title":"Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer","volume":"17","author":"Kyvernitakis","year":"2014","journal-title":"Climacteric"},{"key":"R4-20250512","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/gme.0b013e3181ef975a","article-title":"The Menopause-Specific Quality of Life Questionnaire: psychometric evaluation among breast cancer survivors","volume":"18","author":"Radtke","year":"2011","journal-title":"Menopause"},{"key":"R5-20250512","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1089\/jwh.2019.8262","article-title":"Impact of vulvovaginal symptoms in women diagnosed with cancer: a psychometric evaluation of the day-to-day impact of vaginal aging questionnaire","volume":"30","author":"Toivonen","year":"2021","journal-title":"J Womens Health (Larchmt)"},{"key":"R6-20250512","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1111\/jsm.12156","article-title":"The acceptability, feasibility, and efficacy (phase I\/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer","volume":"10","author":"Juraskova","year":"2013","journal-title":"J Sex Med"},{"key":"R7-20250512","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1186\/s12885-021-08274-w","article-title":"Topical estrogen, testosterone, and vaginal dilator in the prevention of vaginal stenosis after radiotherapy in women with cervical cancer: a randomized clinical trial","volume":"21","author":"Martins","year":"2021","journal-title":"BMC Cancer"},{"key":"R8-20250512","doi-asserted-by":"crossref","first-page":"e0262844","DOI":"10.1371\/journal.pone.0262844","article-title":"Improvements following multimodal pelvic floor physical therapy in gynecological cancer survivors suffering from pain during sexual intercourse: results from a one-year follow-up mixed-method study","volume":"17","author":"Cyr","year":"2022","journal-title":"PLoS One"},{"key":"R9-20250512","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11764-019-00800-x","article-title":"Sexual health and rehabilitation after ovarian suppression treatment (SHARE-OS): a clinical intervention for young breast cancer survivors","volume":"14","author":"Bober","year":"2020","journal-title":"J Cancer Surviv"},{"key":"R10-20250512","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/GME.0b013e31826560da","article-title":"Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer","volume":"20","author":"Baumgart","year":"2013","journal-title":"Menopause"},{"key":"R11-20250512","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/AOG.0000000000004601","article-title":"ACOG Committee Opinion No. 2 (Replaces Committee Opinion No. 659, March 2016):Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer: Clinical Consensus","volume":"138","author":"Suh-Burgmann","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R12-20250512","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JOP.2011.000352","article-title":"Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator","volume":"8","author":"Wills","year":"2012","journal-title":"J Oncol Pract"},{"key":"R13-20250512","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","article-title":"Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial","volume":"3","author":"Melisko","year":"2017","journal-title":"JAMA Oncol"},{"key":"R14-20250512","doi-asserted-by":"crossref","first-page":"e2241743","DOI":"10.1001\/jamanetworkopen.2022.41743","article-title":"Association of vaginal estradiol tablet with serum estrogen levels in women who are postmenopausal secondary analysis of a randomized clinical trial","volume":"5","author":"Mitchell","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R15-20250512","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djac112","article-title":"Systemic or vaginal hormone therapy after early breast cancer: A Danish Observational Cohort Study","volume":"114","author":"Cold","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"R16-20250512","doi-asserted-by":"crossref","first-page":"e1846","DOI":"10.1634\/theoncologist.2020-0417","article-title":"A phase II prospective, randomized, double-blind, placebo-controlled and multicenter clinical trial to assess the safety of 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitor in the adjuvant setting","volume":"25","author":"S\u00e1nchez-Rovira","year":"2020","journal-title":"Oncologist"},{"key":"R17-20250512","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/13697137.2014.947254","article-title":"Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels","volume":"18","author":"Santen","year":"2015","journal-title":"Climacteric"},{"key":"R18-20250512","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ijgc-2019-001034","article-title":"Vaginal estrogen use for genitourinary symptoms in women with a history of uterine, cervical, or ovarian carcinoma","volume":"30","author":"Chambers","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"R19-20250512","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1097\/GME.0000000000001587","article-title":"Expression of androgen receptors in the structures of vulvovaginal tissue","volume":"27","author":"Palacios","year":"2020","journal-title":"Menopause"},{"key":"R20-20250512","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.6004\/jnccn.2022.0052","article-title":"NCCN Guidelines\u00ae Insights: Survivorship, Version 1.2022","volume":"20","author":"Sanft","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R21-20250512","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/GME.0000000000000470","article-title":"Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women","volume":"22","author":"Portman","year":"2015","journal-title":"Menopause"},{"key":"R22-20250512","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00520-017-3960-9","article-title":"Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer"},{"key":"R23-20250512","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/GME.0000000000000624","article-title":"Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo","volume":"23","author":"Eigeliene","year":"2016","journal-title":"Menopause"},{"key":"R24-20250512","doi-asserted-by":"crossref","first-page":"e2255697","DOI":"10.1001\/jamanetworkopen.2022.55697","article-title":"Effect of fractional carbon dioxide vs sham laser on sexual function in survivors of breast cancer receiving aromatase inhibitors for genitourinary syndrome of menopause: the LIGHT randomized clinical trial","volume":"6","author":"Mension","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R25-20250512","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3390\/medicina59010132","article-title":"Emerging use of vaginal laser to treat genitourinary syndrome of menopause for breast cancer survivors: a review","volume":"59","author":"Jugulyt\u0117","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"R26-20250512","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1097\/GME.0000000000001122","article-title":"Efficacy of injecting platelet concentrate combined with hyaluronic acid for the treatment of vulvovaginal atrophy in postmenopausal women with history of breast cancer: a phase 2 pilot study","volume":"25","author":"Hersant","year":"2018","journal-title":"Menopause"},{"key":"R27-20250512","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.2014.60.7366","article-title":"A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial","volume":"33","author":"Goetsch","year":"2015","journal-title":"J Clin Oncol"},{"key":"R28-20250512","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3390\/curroncol30020139","article-title":"Oophorectomy in premenopausal patients with estrogen receptor-positive breast cancer: new insights into long-term effects","volume":"30","author":"Khan","year":"2023","journal-title":"Curr Oncol"},{"key":"R30-20250512","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ucl.2021.06.008","article-title":"Oncology survivorship and sexual wellness for women","volume":"48","author":"Goldman","year":"2021","journal-title":"Urologic Clin North Am"},{"key":"R31-20250512","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.26403","article-title":"Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer","volume":"118","author":"Letourneau","year":"2012","journal-title":"Cancer"},{"key":"R32-20250512","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/molehr\/gaaa043","article-title":"Unraveling the mechanisms of chemotherapy-induced damage to human primordial follicle reserve: road to developing therapeutics for fertility preservation and reversing ovarian aging","volume":"26","author":"Szymanska","year":"2020","journal-title":"Mol Hum Reprod"},{"key":"R33-20250512","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1210\/jc.2016-3723","article-title":"Premature ovarian insufficiency in childhood cancer survivors: a report from the St. Jude Lifetime Cohort","volume":"102","author":"Chemaitilly","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"R34-20250512","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3109\/0284186X.2016.1155738","article-title":"Risk of chemotherapy-induced amenorrhea in patients with breast cancer: a systematic review and meta-analysis","volume":"55","author":"Zavos","year":"2016","journal-title":"Acta Oncol"},{"key":"R35-20250512","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bpobgyn.2022.01.013","article-title":"Gynecological management of the breast cancer survivor","volume":"82","author":"Abel","year":"2022","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"R36-20250512","doi-asserted-by":"crossref","first-page":"11372","DOI":"10.18632\/oncotarget.14532","article-title":"The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients","volume":"8","author":"Vriens","year":"2017","journal-title":"Oncotarget"},{"key":"R37-20250512","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1089\/jwh.2015.5194","article-title":"Understanding fertility in young female cancer patients","volume":"24","author":"Waimey","year":"2015","journal-title":"J Womens Health (Larchmt)"},{"key":"R38-20250512","first-page":"e7586","article-title":"The genitourinary syndrome of menopause: an overview of the recent data","volume":"12","author":"Angelou","year":"2020","journal-title":"Cureus"},{"key":"R39-20250512","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.fertnstert.2013.08.018","article-title":"Sexual dysfunction in women with cancer","volume":"100","author":"Falk","year":"2013","journal-title":"Fertil Steril"},{"key":"R40-20250512","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1080\/01443615.2022.2035329","article-title":"Vaginal mucositis in patients with gynaecological cancer undergoing (chemo-)radiotherapy: a retrospective analysis","volume":"42","author":"Robijns","year":"2022","journal-title":"J Obstet Gynaecol"},{"key":"R41-20250512","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bpobgyn.2018.07.008","article-title":"Ovarian effects of radiation and cytotoxic chemotherapy damage","volume":"55","author":"Cosgrove","year":"2019","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"R42-20250512","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/humrep\/deg016","article-title":"The radiosensitivity of the human oocyte","volume":"18","author":"Wallace","year":"2003","journal-title":"Hum Reprod"},{"key":"R43-20250512","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ygyno.2015.11.010","article-title":"Maintaining sexual health throughout gynecologic cancer survivorship: a comprehensive review and clinical guide","volume":"140","author":"Huffman","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R44-20250512","first-page":"CD007291","article-title":"Vaginal dilator therapy for women receiving pelvic radiotherapy","volume":"2014","author":"Miles","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R45-20250512","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1471-0528.2010.02502.x","article-title":"Dilating the vagina to prevent damage from radiotherapy: systematic review of the literature","volume":"117","author":"Johnson","year":"2010","journal-title":"BJOG"},{"key":"R46-20250512","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for pre-menopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"key":"R47-20250512","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"key":"R48-20250512","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00001813-200409000-00003","article-title":"Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients","volume":"15","author":"Morales","year":"2004","journal-title":"Anticancer Drugs"},{"key":"R49-20250512","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"R50-20250512","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"R51-20250512","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R52-20250512","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"R53-20250512","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R54-20250512","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"R55-20250512","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"R56-20250512","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/cncr.33915","article-title":"Intersectionality and cancer survivorship: sexual orientation and racial\/ethnic differences in physical and mental health outcomes among female and male cancer survivors","volume":"128","author":"Boehmer","year":"2022","journal-title":"Cancer"},{"key":"R57-20250512","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/GME.0000000000001249","article-title":"Decreasing menopausal symptoms of Asian American breast cancer survivors through a technology-based information and coaching\/support program","volume":"26","author":"Im","year":"2019","journal-title":"Menopause"},{"key":"R58-20250512","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/07347332.2011.651259","article-title":"Psychosocial concerns of young African American breast cancer survivors","volume":"30","author":"Lewis","year":"2012","journal-title":"J Psychosoc Oncol"},{"key":"R59-20250512","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0193945909354343","article-title":"Menopausal symptoms among four major ethnic groups in the United States","volume":"32","author":"Im","year":"2010","journal-title":"West J Nurs Res"},{"key":"R60-20250512","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1037\/a0016501","article-title":"Burden of psychiatric morbidity among les- bian, gay, and bisexual individuals in the California Quality of Life Survey","volume":"118","author":"Cochran","year":"2009","journal-title":"J Abnorm Psychol"},{"key":"R61-20250512","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1037\/0022-006X.71.1.53","article-title":"Prevalence of mental disorders, psychological distress, and mental health services use among lesbian, gay, and bisexual adults in the United States","volume":"71","author":"Cochran","year":"2003","journal-title":"J Consult Clin Psychol"},{"key":"R62-20250512","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1471-244X-8-70","article-title":"A systematic review of mental disorder, suicide, and deliberate self harm in lesbian, gay and bisexual people","volume":"8","author":"King","year":"2008","journal-title":"BMC Psychiatry"}],"container-title":["Clinical Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T11:14:06Z","timestamp":1747048446000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/grf.0000000000000848","relation":{},"ISSN":["0009-9201"],"issn-type":[{"value":"0009-9201","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,18]]}}}